A comparative study of auranofin, gold sodium thiomalate, and D-penicillamine in rheumatoid arthritis: a progress report

J Rheumatol Suppl. 1982 Jul-Aug:8:197-200.

Abstract

We compared auranofin (AF) in a single blind multi-centre study with gold sodium thiomalate and D-penicillamine in the treatment of rheumatoid arthritis. Adult patients with disease duration 6-60 months without previous treatment with gold salts with persistent active disease, were included. Thirty-nine patients, 13 in each treatment group, have so far been entered. Cumulative toxicity data and some results of efficacy assessments in those completing 9 months of treatment are presented. AF is very well tolerated, judgment concerning efficacy must await the end of the trial.

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial

MeSH terms

  • Arthritis, Rheumatoid / drug therapy*
  • Auranofin
  • Aurothioglucose / adverse effects
  • Aurothioglucose / analogs & derivatives*
  • Aurothioglucose / therapeutic use
  • Female
  • Gold / analogs & derivatives*
  • Gold Sodium Thiomalate / adverse effects
  • Gold Sodium Thiomalate / therapeutic use*
  • Humans
  • Male
  • Middle Aged
  • Outcome and Process Assessment, Health Care
  • Penicillamine / adverse effects
  • Penicillamine / therapeutic use*
  • Time Factors

Substances

  • Gold Sodium Thiomalate
  • Aurothioglucose
  • Auranofin
  • Gold
  • Penicillamine